[
  {
    "ts": null,
    "headline": "2 Incredibly Cheap Dividend Stocks to Buy Now",
    "summary": "Yes, there are bargains out there for investors seeking income-paying stocks.",
    "url": "https://finnhub.io/api/news?id=071d0b974417358526bb7202e7ad229870f56a33df1d26854f70d99a9ffa203f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771538460,
      "headline": "2 Incredibly Cheap Dividend Stocks to Buy Now",
      "id": 139152825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Yes, there are bargains out there for investors seeking income-paying stocks.",
      "url": "https://finnhub.io/api/news?id=071d0b974417358526bb7202e7ad229870f56a33df1d26854f70d99a9ffa203f"
    }
  },
  {
    "ts": null,
    "headline": "Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights",
    "summary": "DUBLIN, February 19, 2026--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights",
    "url": "https://finnhub.io/api/news?id=c70a868539b746f683baf4f94bf88f3a88466b76cba8c1c168b35f3414df177a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771535100,
      "headline": "Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights",
      "id": 139152176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "DUBLIN, February 19, 2026--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights",
      "url": "https://finnhub.io/api/news?id=c70a868539b746f683baf4f94bf88f3a88466b76cba8c1c168b35f3414df177a"
    }
  },
  {
    "ts": null,
    "headline": "Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space",
    "summary": "Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B. Riley initiated coverage of Cytokinetics (NASDAQ:CYTK) with a Buy rating and a $108 price target. The positive stance underscores the research firm’s confidence about the company’s ability to capture market share in the cardiac myosin […]",
    "url": "https://finnhub.io/api/news?id=357881fb8c9e6d680ef39cb5f6f2e05e1e19c501e17aa6127c2477ed31ea7b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771530084,
      "headline": "Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space",
      "id": 139151505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B. Riley initiated coverage of Cytokinetics (NASDAQ:CYTK) with a Buy rating and a $108 price target. The positive stance underscores the research firm’s confidence about the company’s ability to capture market share in the cardiac myosin […]",
      "url": "https://finnhub.io/api/news?id=357881fb8c9e6d680ef39cb5f6f2e05e1e19c501e17aa6127c2477ed31ea7b67"
    }
  },
  {
    "ts": null,
    "headline": "This Is A Stock Picker's Market",
    "summary": "Next-gen investing expertsÂ Julia Ostian, Jack Bowman, and Kenio FontesÂ share their investment strategies and top stock picks.",
    "url": "https://finnhub.io/api/news?id=1fef686c9d9521f74cfa19c11b0b9da8fd6332ca8675952b5ce817c2d31ea0ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771521600,
      "headline": "This Is A Stock Picker's Market",
      "id": 139152389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221147115/image_2221147115.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Next-gen investing expertsÂ Julia Ostian, Jack Bowman, and Kenio FontesÂ share their investment strategies and top stock picks.",
      "url": "https://finnhub.io/api/news?id=1fef686c9d9521f74cfa19c11b0b9da8fd6332ca8675952b5ce817c2d31ea0ca"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: I'm Buying Post Earnings",
    "summary": "Bristol-Myers: I'm Buying Post Earnings",
    "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771517342,
      "headline": "Bristol-Myers: I'm Buying Post Earnings",
      "id": 139151899,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1"
    }
  },
  {
    "ts": null,
    "headline": "Where is Janux Therapeutics (JANX) Headed According to Analysts?",
    "summary": "Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc. (NASDAQ:JANX) on January 23, setting a price target of $50.00. The rating update came after Janux Therapeutics, Inc. (NASDAQ:JANX) announced on January 22 a collaboration and exclusive worldwide license […]",
    "url": "https://finnhub.io/api/news?id=f5e6938b221e8a98ffb48deb114fffd142330021503ae05b9e0bbb377033e46b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771513170,
      "headline": "Where is Janux Therapeutics (JANX) Headed According to Analysts?",
      "id": 139149143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc. (NASDAQ:JANX) on January 23, setting a price target of $50.00. The rating update came after Janux Therapeutics, Inc. (NASDAQ:JANX) announced on January 22 a collaboration and exclusive worldwide license […]",
      "url": "https://finnhub.io/api/news?id=f5e6938b221e8a98ffb48deb114fffd142330021503ae05b9e0bbb377033e46b"
    }
  },
  {
    "ts": null,
    "headline": "What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in support of its national campaign in fighting food insecurity. Management reported that the Food is Health: Nourishing Communities, Advancing […]",
    "url": "https://finnhub.io/api/news?id=2c1f2591e34dd7e611afe9979fd5f86b489e40f21aa2cc490483625031009ea3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512847,
      "headline": "What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?",
      "id": 139149144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in support of its national campaign in fighting food insecurity. Management reported that the Food is Health: Nourishing Communities, Advancing […]",
      "url": "https://finnhub.io/api/news?id=2c1f2591e34dd7e611afe9979fd5f86b489e40f21aa2cc490483625031009ea3"
    }
  },
  {
    "ts": null,
    "headline": "Iberdomide Review And AI Alliance Add New Angles To BMY Outlook",
    "summary": "FDA accepts Bristol Myers Squibb's New Drug Application for iberdomide for relapsed or refractory multiple myeloma and grants Breakthrough Therapy Designation and Priority Review under Project Orbis. Bristol Myers Squibb joins an AI driven data sharing alliance with Evinova and other large pharmaceutical companies to support global clinical development. Both developments highlight progress in oncology research and digital drug development initiatives at Bristol Myers Squibb. For investors...",
    "url": "https://finnhub.io/api/news?id=a4886aeef322dd80df7523677f19532891b636125aa249257a43115b6cf04599",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771510131,
      "headline": "Iberdomide Review And AI Alliance Add New Angles To BMY Outlook",
      "id": 139149145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "FDA accepts Bristol Myers Squibb's New Drug Application for iberdomide for relapsed or refractory multiple myeloma and grants Breakthrough Therapy Designation and Priority Review under Project Orbis. Bristol Myers Squibb joins an AI driven data sharing alliance with Evinova and other large pharmaceutical companies to support global clinical development. Both developments highlight progress in oncology research and digital drug development initiatives at Bristol Myers Squibb. For investors...",
      "url": "https://finnhub.io/api/news?id=a4886aeef322dd80df7523677f19532891b636125aa249257a43115b6cf04599"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "summary": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771500536,
      "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
      "id": 139149509,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech SE (BNTX) Rallying on Solid Oncology Strategy",
    "summary": "BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from an Outperform and set a $113 price target. The downgrade is in response to the stock rallying from its December lows […]",
    "url": "https://finnhub.io/api/news?id=ab0ef341baf0cd87eeb264f1dd1340ce4898fcfde8ff5760a8f03d9749a9a3f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771490592,
      "headline": "BioNTech SE (BNTX) Rallying on Solid Oncology Strategy",
      "id": 139144267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from an Outperform and set a $113 price target. The downgrade is in response to the stock rallying from its December lows […]",
      "url": "https://finnhub.io/api/news?id=ab0ef341baf0cd87eeb264f1dd1340ce4898fcfde8ff5760a8f03d9749a9a3f2"
    }
  }
]